This website has been developed by Novo Nordisk UK and is intended for GB-based adolescent patients aged 12–17 years who have been prescribed Wegovy® and their carers. Before verifying and entering this website, please ask your parent, carer, or guardian to access this information with you. By verifying, you confirm that you and your parent, carer, or guardian wish to access the information on this website.
The information on this website does not replace the patient information leaflet, which you are advised to read in full. It is not intended as a substitute for clinical advice provided by your healthcare professional. Please contact your healthcare professional if you have any questions about your treatment and for clinical advice.
This website does not collect any information that could identify you, but may use limited tools, such as cookies, to understand how the website is used. You, your parent, carer or guardian can read more about this on our Privacy Policy and Cookies Policy.
To ensure you receive the information that meets your needs, please tell us who you are:
I am a member of the public based in the UK →
I am a healthcare professional or other relevant decision maker based in Great Britain →
I am a GB-based adult patient who has been prescribed Wegovy® →
Reporting of side effects
This medicine is subject to additional
monitoring. This will allow quick identification of new safety
information promptly. You can help by reporting any side effects you
may get. See https://yellowcard.mhra.gov.uk/ for how to report
side effects.
If you get any side effects, talk to your
doctor, pharmacist or nurse. This includes any possible side effects
not listed in the package leaflet. You can also report side effects
directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. Side effects
should also be reported to Novo Nordisk Limited (Telephone Novo
Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored
for training purposes. By reporting side effects, you can help provide
more information on the safety of this medicine.